PDS Biotechnology Corporation announced that they will host a company conference call on June 8, 2021, at 8:00 am ET, following the oral presentation of preliminary data of PDS0101 at the 2021 American Society of Clinical Oncology Annual Meeting. A press release summarizing the abstract data was issued on May 20.
PDS Biotechnology Corporation is a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology.
Currently, the full abstract for #2501 is titled Phase II evaluation of the triple combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16 positive malignancies, is available on the ASCO meeting website. A copy of PDS Biotechnology Corporation presentation will be available on June 8th on the scientific presentations and publications page of PDS Biotech’s website. The ones who are willing to take part in the conference can do the registration which is now open and a live webcast of the event will be available online in the investor relations section of the company’s website. A replay will be available on the company website for 90 days following the webcast